The bill amends existing laws to empower licensed pharmacists to prescribe and dispense FDA-approved tobacco cessation drug therapies to "qualified patients," defined as individuals aged 18 and older who are committed to a structured cessation program and informed about the associated risks and side effects. Pharmacists must complete designated tobacco cessation education and are required to refer high-risk patients to their primary care providers. They are also mandated to adhere to updated clinical guidelines and provide educational counseling on cessation strategies.

Additionally, the bill mandates that all group health insurance contracts and medical expense policies issued or renewed after January 1, 2026, must cover tobacco cessation drug therapies and the services provided by pharmacists within their lawful scope of practice. Health insurers are required to include an adequate number of pharmacists in their provider networks and cannot impose unnecessary supervisory requirements for reimbursement. The legislation aims to improve access to tobacco cessation resources while recognizing pharmacists as essential healthcare providers. It also specifies that nonprofit medical service corporations cannot require supervision or referral from other healthcare providers for reimbursement to pharmacists, although they are not obligated to pay for duplicative services provided by both a pharmacist and another healthcare provider.